Cart (0 Items)
Your cart is currently empty.
View ProductsBrand | ProteoGenix |
---|---|
Product type | Elisa assay kits |
Size | 96T |
Product name | Toripalimab ELISA Kit |
---|---|
Delivery condition | Blue ice (+4°) |
Storage condition | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
Brand | ProteoGenix |
Size | 96T |
Reference | KPTX256 |
Note | For research use only. |
Sample type | Plasma, Serum |
Immunogen | Toripalimab |
Toripalimab ELISA Kit is a highly sensitive and specific immunoassay designed for the quantitative measurement of Toripalimab in biological samples. This innovative kit is based on the principle of enzyme-linked immunosorbent assay (ELISA) and is used for the detection of Toripalimab, a promising therapeutic antibody targeting PD-1 (programmed death-1) receptor.
Toripalimab, also known as JS001, is a fully humanized immunoglobulin G4 (IgG4) monoclonal antibody. It has a molecular weight of approximately 146 kDa and is composed of two heavy chains and two light chains. The heavy chains consist of constant (Fc) and variable (Fab) regions, while the light chains have only variable regions. The variable regions of Toripalimab are responsible for its binding to PD-1 receptor on the surface of immune cells.
The Fc region of Toripalimab is responsible for its effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These effector functions play a crucial role in the anti-tumor activity of Toripalimab.
Toripalimab is a potent immune checkpoint inhibitor that targets PD-1, a key receptor involved in regulating the immune response. PD-1 is expressed on the surface of T cells and helps in maintaining immune tolerance by suppressing the activity of T cells. However, in cancer, PD-1 is exploited by tumor cells to evade detection and destruction by the immune system.
Toripalimab binds to PD-1 and blocks its interaction with its ligands, PD-L1 and PD-L2, thereby preventing the suppression of T cell activity. This leads to the reactivation of T cells and enhances their ability to recognize and destroy cancer cells. Toripalimab has shown promising results in clinical trials and has been approved for the treatment of various types of cancer, including melanoma, non-small cell lung cancer, and nasopharyngeal carcinoma.
Toripalimab ELISA Kit is a valuable tool for the detection and quantification of Toripalimab in biological samples. It has been extensively used in preclinical and clinical studies to monitor the pharmacokinetics of Toripalimab and evaluate its efficacy in patients. This kit provides a simple, fast, and reliable method for the measurement of Toripalimab levels, which is essential for optimizing the dosing regimen and predicting treatment response.
Moreover, Toripalimab ELISA Kit has also been used to study the pharmacodynamics of Toripalimab. By measuring the levels of Toripalimab in different samples, such as serum, plasma, and tissue, this kit allows researchers to understand the distribution, metabolism, and elimination of Toripalimab in the body. This information is crucial for the development of new treatment strategies and improving the therapeutic efficacy of Toripalimab.
Toripalimab ELISA Kit is a powerful tool for the measurement of Toripalimab, a promising therapeutic antibody targeting PD-1 receptor. This kit provides a simple and reliable method for the detection and quantification of Toripalimab, which is essential for monitoring its pharmacokinetics and pharmacodynamics. With its high sensitivity and specificity, Toripalimab ELISA Kit is a valuable asset for researchers and clinicians working towards improving cancer treatment and patient outcomes.
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.